T. Rowe Price Investment Management, Inc., a registered investment adviser, initiated a new position in Cytokinetics, Incorporated (NASDAQ:CYTK) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 17,716,372 shares of the Healthcare company, valued at approximately $1.1B as of the filing date.
Cytokinetics, Incorporated's stock currently trades at $68.30 with a market capitalization of $7.2B.